KRN7000 applied to viral research:

Invariant NKT cell response to dengue virus infection in human

α-Galactosylceramide potently augments M2e-induced protective immunity against highly pathogenic H5N1 avian influenza virus infection in mice

Preclinical efficacy studies of influenza A haemagglutinin precursor cleavage loop peptides as a potential vaccine

Enhanced ability of peripheral invariant natural killer T cells to produce IL-13 in chronic hepatitis C virus infection

Severe loss of invariant NKT cells exhibiting anti-HTLV-1 activity in patients with HTLV-1-associated disorders

Nasal vaccination with P6 outer membrane protein and alpha-galactosylceramide induces nontypeable Haemophilus influenzae-specific protective immunity associated with NKT cell activation and dendritic cell expansion in nasopharynx

CD1d-dependent B-cell help by NK-like T cells leads to enhanced and sustained production of Bacillus anthracis lethal toxin-neutralizing antibodies

{alpha}-Galactosylceramide as a Therapeutic Agent for Pulmonary Mycobacterium tuberculosis Infection

A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system

The mucosal adjuvant effect of alpha-galactosylceramide for induction of protective immunity to sexually transmitted viral infection.

Alpha-C-galactosylceramide as an adjuvant for a live attenuated influenza virus vaccine

α-Galactosylceramide and Novel Synthetic Glycolipids Directly Induce the Innate Host Defense Pathway and Have Direct Activity against Hepatitis B and C Viruses

alpha-Galactosylceramide protects mice from lethal Coxsackievirus B3 infection and subsequent myocarditis

Mechanism of NKT cell activation by intranasal coadministration of alpha-galactosylceramide, which can induce cross-protection against influenza viruses

alpha-Galactosylceramide can act as a nasal vaccine adjuvant inducing protective immune responses against viral infection and tumor

Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines

Activation of Valpha14+ Natural Killer T Cells by alpha-Galactosylceramide Results in Development of Th1 Response and Local Host Resistance in Mice Infected with Cryptococcus neoformans

Combined NKT cell activation and influenza virus vaccination boosts memory CTL generation and protective immunity

Enhanced gamma interferon production through activation of Valpha14(+) natural killer T cells by alpha-galactosylceramide in interleukin-18-deficient mice with systemic cryptococcosis

Activation of invariant NKT cells enhances the innate immune response and improves the disease course in influenza A virus infection

Regulation of airway eosinophil and neutrophil infiltration by alpha-galactosylceramide in a mouse model for respiratory syncytial virus (RSV) vaccine-augmented disease

B subunit of Shiga toxin-based vaccines synergize with alpha-galactosylceramide to break tolerance against self antigen and elicit antiviral immunity

Randomized placebo controlled phase I/II trial of alpha-galactosylceramide for the treatment of chronic hepatitis C

Alpha-galactosylceramide promotes killing of Listeria monocytogenes within the macrophage phagosome through invariant NKT-cell activation

Incorporation of NKT cell-activating glycolipids enhances immunogenicity and vaccine efficacy of Mycobacterium bovis bacillus Calmette-Guerin

Cd1d-dependent regulation of bacterial colonization in the intestine of mice

alpha -galactosylceramide-activated Valpha 14 natural killer T cells mediate protection against murine malaria

Circulating Valpha24+Vbeta11+ NKT cell numbers and dendritic cell CD1d expression in hepatitis C virus infected patients

Activation of natural killer (NK) T cells during murine cytomegalovirus infection enhances the antiviral response mediated by NK cells

NK T cells contribute to expansion of CD8(+) T cells and amplification of antiviral immune responses to respiratory syncytial virus

Back to top


New 7DW8-5 glycolipid


Now available 7DW8-5 glycolipid derivative of Alpha-GalCer for human and mice iNKT immunoresearch


Meet Funakoshi Company
at the following meetings:

NIH Research Festival
Bethesda, MD
September 13-14, 2018

San Diego, CA
December 8-12